Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Thanks BBBB
No leak, I believe it could be off Myles’s message regarding AVCT. If someone could add a link to the Twitter comments that would be great.
Rather be derogatory, perhaps be useful instead? IT systems glitch.
Hi Oak, I can attempt to try and explain simply however, someone with a greater understanding might correct me. From my understanding, with the press focusing on the Moonshot programme which has LFD Anitgen tests as it’s pinnacle, demand for Avacta’s shares have soared. Avacta is known in the Investment world however as everyone knows, we do not have the LFD Anitgen product up and ready just yet. There have been some major buys today, one amounting as £300k. This shot the price up astronomically. Traders sensed that the price would consolidate with people taking profit. The sell off was amplified by ‘noise’ that the government awarded a contract to a competitor of Avacta. Hope this helps
Bump
Bella - Not too sure. I believe it could be in the UK and EU. But as it's a South Korean company and a European country, I can't imagine the Government having the ability to take control of the manufacturing aspect unlike their position with Avacta.
Unsure whether it is just Nasal or not as it is stated on the Government website as Saliva - https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/lateral-flow-devices-results
Then again, how accurate is the Website.. It doesn't show as a Saliva Antigen LFT here: https://chs.asu.edu/diagnostics-commons/testing-commons
The Government were indeed talking about Avacta as they talk about new tech still being developed (Avacta) however, I think they were also referring to SD Bio sensor and will do for a quick win.
https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/lateral-flow-devices-results
How do you link on BB?
Admittedly, I thought they were nasal based.
However, we know that there sensitivity is weak compared to what Avacta is aiming for:
WHO standard
In September the World Health Organization approved two “lateral flow” antigen tests, which display a result like a pregnancy test, are small and portable, and deliver a result in just 15-30 minutes.6 Made by the South Korean company SD Biosensor and the US company Abbott, they are the first rapid tests to meet WHO’s specifications. An independent evaluation of the SD Biosensor test by the Foundation for Innovative New Diagnostics (FIND) found that it had a clinical specificity of 99.3% and a clinical sensitivity of 76.6%.7 No independent evaluation of the Abbott test is yet available.
As Al said, there will be competition but he has no worry that whatever Avacta will produce, Avacta will sell
Bump
I would apply a very conservative x3 ratio as this is a one off event (for now). I expect to be wrong and I hope that I am.
Thank you Italyal for your summary. Greatly appreciated
Thanks Kong1. If they’ve taken share equity over cash payment that bodes very well
Previous issue of equity were gifted to Group employees & Service provider. A week after, a manufacturing partner (BBI) came onboard. The issue of equity before then were to group employees only. There was an RNS that day. This could all be mindless thoughts but if someone having previous experience or knowledge regarding these items could provide a summary that would be greatly appreciated
I think I have the answer to my question..
Service Provider” means any employee, director or consultant.
Defined by a SEC report. Could be different but would make sense..
Maen, good spot on the service provider. Does anyone have a good understanding on what the service provider could be?
Quite a large share of equity.. Do people think it’s because they’ve achieved a target which therefore gifts the relevant colleagues share of equity?
Welcome back Indy
Bluemoon, while I don't venture across to NCYT or ODX board often, I cannot agree with your statement enough. The majority of COVID plays are going to do exceptional well and rather than the historic bickering (on all sides), I hope we can look to celebrate with each other over a pint once we have tackled COVID together. I look forward to that date...
DOH, where did you ascertain that information regard Mologic's Tech Transfer and their AGM? I cannot locate this information on the internet
City I appreciate your response and do I agree with it slightly however, if you were in Avacta’s position and for them to come out as the first company to produce the ‘Holy Grail’ and for them Mologic to come out with the second ‘Holy Grail’ by using Affirmers... now that is a headline
We already have a partnership with Mologic which gives them access to our affimers... Other competitors haven’t been able to make the needed requirements yet Mologic are pursuing us for the ‘holy grail’. As Phantom says, AS has stated he’s very happy to liscence out the Affimers but I do agree that an RNS should have been stated if this is the case